Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02433665 · ClinicalTrials.gov registry record · NA

Customized Contrast Media Dose Clinical Trial

A NA study, sponsored by Duke University.

Terminated
Registry status
NA
Development phase
166
Enrollment target

NCT02433665: Clinical Trial NA study, sponsored by Duke University.

NCT02433665 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 166 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02433665, a NA study, was terminated before completion, sponsored by Duke University.

TERMINATED
Registry status
NA
Development phase
166 participants
Enrollment target

Study Summary

1. To determine if a formula derived from PCA using specific patient parameters can be used to determine the individual contrast material dose and provide a more consistent level of vascular and parenchymal enhancement during MDCT scanning of the abdomen and pelvis. 2. Up to 500 adult patients referred for a "CT of the abdomen and pelvis with contrast material" will be recruited to participate in this trial. Single CT axial slices (n=2) will be obtained at the level of the L4 pedicle and the supra-acetabular pelvis using a field-of-view that includes all of the patient. From patient measurements (height, weight, body dimensions), a customized dose of contrast material will be specified according to the derived formula for 400 subjects. One hundred subjects will receive the usual fixed contrast dose. 3. Enhancement data in HU will be measured from the CT scans using manually-placed ROIs on the upper abdominal aorta, main portal vein and liver parenchyma, avoiding visible liver tumors, major blood vessels and artifacts, if present. This enhancement data will be used to determine the patient-to-patient variability.

Interventions

  • DRUG Iopamidol
  • DEVICE Mydose

Trial Details

FieldValue
Enrollment Target 166 participants
Start Date 2015-08
Est. Completion 2016-10-06
Phase NA
Duke University

1,725 total trials

Why NCT02433665 stopped before completion

NCT02433665 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 2 interventions - of which Iopamidol is the first listed.

NCT02433665 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02433665 about?

NCT02433665 is a clinical study titled "Customized Contrast Media Dose Clinical Trial". 1. To determine if a formula derived from PCA using specific patient parameters can be used to determine the individual contrast material dose and provide a more consistent level of vascular and parenchymal enhancement during MDCT scanning of the abdomen and pelvis. 2. Up to 500 adult patients refer...

What is the current status of trial NCT02433665?

This trial is currently terminated. It is a NA study. The enrollment target is 166 participants. The study started on 2015-08. Estimated completion is 2016-10-06.

What interventions are being tested in trial NCT02433665?

The interventions under investigation include: Iopamidol (DRUG), Mydose (DEVICE).

Who is sponsoring clinical trial NCT02433665?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02433665's enrollment target sits among peer trials

166 625th of 2000 higher than 1,375 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02747303 · 166 participants · Phase 2

    Frameless Stereotactic Radiosurgery for Intact Brain Metastases

  • NCT03806283 · 166 participants

    Mechanisms of Pregnancy Vascular Adaptations

  • NCT04040452 · 166 participants · Phase 4

    Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery

  • NCT04375813 · 166 participants · Phase 2

    Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02433665, the US trial registry maintained by the National Library of Medicine. NCT02433665 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.